Contact l Sitemap

home industries issues reasearch weblog press

Home  » Industries » Pharmaceuticals

US: Tauzin Raised Six-Figure Sum From Drug Makers



by Steven WeissCenter for Responsive Politics
December 15th, 2004


Rep. W. J. "Billy" Tauzin (R-La.), who today was named president
and CEO of the Pharmaceutical Research and Manufacturers of
America (PhRMA), raised more than $218,000 in his campaign
account from pharmaceutical manufacturers over the past 15 years.

He collected increasing amounts over time from drug companies,
topping out at $91,500 in the 2002 election cycle. It was the
fourth-highest total from the industry to a member of the House
that cycle. It was also the first cycle for Tauzin as chairman
of the powerful House Energy and Commerce Committee, which has
jurisdiction over the drug industry.

Tauzin raised $41,500 from pharmaceutical manufacturers in the
current cycle, even though he was not a candidate for
reelection. He collected $9,000 from the PhRMA political action
committee since 1997.

Drug companies have contributed $8.1 million since 2003 to
federal candidates and political parties, 69 percent to
Republicans. During the 2002 election cycle, when unlimited soft
money contributions to the political parties were still allowed,
pharmaceutical manufacturers gave $21.7 million, 80 percent to
the GOP.

The industry spends millions lobbying the federal government
each year -- PhRMA spent more than $8 million on lobbying in the
first half of this year alone. Drug makers also spend millions
more on nonprofits active in federal elections. Public Citizen
estimates that PhRMA poured $41 million into 501(c) groups in
2002. Such groups are not required to disclose their donors.





This site contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available in our efforts to advance understanding of environmental, political, human rights, economic, democracy, scientific, and social justice issues, etc. We believe this constitutes a 'fair use' of any such copyrighted material as provided for in section 107 of the US Copyright Law. In accordance with Title 17 U.S.C. Section 107, the material on this site is distributed without profit to those who have expressed a prior interest in receiving the included information for research and educational purposes. For more information go to: http://www.law.cornell.edu/uscode/17/107.shtml. If you wish to use copyrighted material from this site for purposes of your own that go beyond 'fair use', you must obtain permission from the copyright owner.